Skip to Content

FluMist Quadrivalent (influenza virus vaccine, live, trivalent) Disease Interactions

There are 4 disease interactions with FluMist Quadrivalent (influenza virus vaccine, live, trivalent):

Major

Influenza vaccine (applies to FluMist Quadrivalent) GBS

Major Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome

The use of influenza vaccine has been associated with an elevated risk of Guillain-Barré syndrome (GBS). It is not recommended to administer this vaccine if GBS has occurred within 6 weeks following previous influenza vaccination. Care and close monitoring is recommended and consideration of the potential benefits and risks should be assessed.

Major

Influenza vaccine (applies to FluMist Quadrivalent) neurologic disorders

Major Potential Hazard, Moderate plausibility.

Influenza vaccine should be withheld, pending stabilization, in patients with active neurologic disorders associated with changing neurological status. Neurologic signs or symptoms following administration of an influenza vaccine is a contraindication to future use.

References

  1. "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.
Major

Vaccination (applies to FluMist Quadrivalent) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Fever

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Varivax (varicella virus vaccine live)." Merck & Co, Inc, West Point, PA.
  4. "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.
  5. "Product Information. Typhim Vi (typhoid vaccine)." Connaught, Swiftwater, PA.
  6. "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.
  7. "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.
  8. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
  9. "Product Information. Menomune-A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught, Swiftwater, PA.
  10. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
  11. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  12. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  13. "Product Information. Orimune (poliovirus vaccine, live, oral, trivalent)." Lederle Laboratories, Philadelphia, PA.
  14. "Product Information. Mumpsvax (mumps virus vaccine (live).)." Merck & Co, Inc, West Point, PA.
  15. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
View all 15 references
Moderate

Intranasal influenza vaccine (applies to FluMist Quadrivalent) asthma

Moderate Potential Hazard, Moderate plausibility.

Intranasal influenza vaccine has been associated with increased wheezing. Caution is recommended when using intranasal influenza vaccine in children with recurrent wheezing and asthmatic patients as these patients may be at an increased risk of developing wheezing.

FluMist Quadrivalent (influenza virus vaccine, live, trivalent) drug interactions

There are 307 drug interactions with FluMist Quadrivalent (influenza virus vaccine, live, trivalent)

More about FluMist Quadrivalent (influenza virus vaccine, live, trivalent)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.